Table 2.
Antibiotic Susceptibility of GNB Isolates in This Study
| Antibiotic Agent | No. of Nonsusceptible Isolates/No. of Tested Isolates (%)a | ||||
|---|---|---|---|---|---|
| Site 1 (N = 96) | Site 2 (N = 75) | Site 3 (N = 43) | Site 4 (N = 16) | Total (N = 230)b | |
| Gentamicinc | 20/93 (21.5) | 11/73 (15.1) | 0/41 (0.0) | 2/16 (12.5) | 33/223 (14.8) |
| Piperacillin-tazobactam | 7/87 (8.0) | 3/71 (4.2) | 2/33 (6.1) | 2/10 (20) | 14/201 (7.0) |
| Third-generation cephalosporin agents or cefepimed | 10/94 (10.6) | 5/73 (6.8) | 6/41 (14.6) | 1/14 (7.1) | 22/222 (9.9) |
| Carbapenem agents | 1/94 (1.1) | 0/71 (0.0) | 0/38 (0.0) | 0/14 (0.0) | 1/217 (0.5) |
| ≥2 of these agents | 5/94 (5.3) | 4/73 (5.6) | 2/41 (4.9) | 2/16 (12.5) | 13/224 (5.8) |
| ≥3 of these agents | 1/94 (1.1) | 1/73 (1.3) | 0/38 (0.0) | 0/14 (0.0) | 2/219 (0.9) |
Abbreviation: GNB, gram-negative bacilli.
aNot every isolate underwent antimicrobial susceptibility testing.
bSome infections were caused by >1 GNB.
cRates of gentamicin susceptibility were significantly different among the study sites (P < .05).
dNonsusceptibility to ceftazidime was used to determine nonsusceptibility of P aeruginosa to third-generation cephalosporin agents.